Pernille Holmager
Overview
Explore the profile of Pernille Holmager including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ewers B, Blond M, Kelstrup L, Foghsgaard S, Bergholt T, Hansen M, et al.
BMJ Open
. 2025 Feb;
15(2):e089231.
PMID: 39961720
Introduction: Gestational diabetes mellitus (GDM) poses health risks due to hyperglycaemia, which can lead to clinical complications for mother and child. While dietary therapy serves as first-line treatment, approximately one-third...
2.
Ankerstjerne M, Giovannoni S, Christensen L, Moller S, Holmager P, Knigge U, et al.
Pediatr Blood Cancer
. 2024 Nov;
72(2):e31420.
PMID: 39579111
Background: Neuroendocrine tumors (NETs), although rare, are considered one of the most common gastrointestinal and bronchopulmonary pediatric neoplasms. We aimed to determine the incidence, tumor characteristics, management, and outcome of...
3.
Holmager P, Christensen M, Norgaard K, Schmidt S
J Diabetes Sci Technol
. 2024 Oct;
19(2):286-291.
PMID: 39417493
Introduction: Automated insulin delivery (AID) systems have improved glycemic control in individuals with type 1 diabetes (T1D) but overweight and increased cardiovascular risk remain a challenge. Glucagon-like peptide-1 receptor agonists...
4.
Petersen S, Moller S, Slott C, Krogh J, Hansen C, Kjaer A, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539524
Background: Given the rarity and heterogeneity of pancreatic neuroendocrine neoplasms (pNEN), treatment algorithms and sequencing are primarily guided by expert opinions with limited evidence. Aim: To investigate overall survival (OS),...
5.
Slott C, Langer S, Moller S, Krogh J, Klose M, Hansen C, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201631
Background: Small intestinal neuroendocrine tumors (siNET) are one of the most common neuroendocrine neoplasms. Radical surgery is the only curative treatment. Method: We utilized a single-center study including consecutive patients...
6.
Moller S, Langer S, Slott C, Krogh J, Hansen C, Kjaer A, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201527
Introduction: The prognosis and impact of different prognostic factors in pancreatic neuroendocrine neoplasms (pNEN) remain controversial. Aim: To investigate prognostic factors for recurrence-free survival and disease-specific survival in patients with...
7.
Holmager P, Langer S, Kjaer A, Ringholm L, Garbyal R, Hansen C, et al.
Curr Oncol Rep
. 2024 Jan;
26(2):114-120.
PMID: 38168835
Purpose Of Review: To summarize the literature from the last 5 years on treatment of appendiceal neuroendocrine neoplasms (aNEN). Furthermore, to evaluate the prognostic significance of lymph node metastases, indications...
8.
Norgaard S, Soholm J, Mathiesen E, Norgaard K, Clausen T, Holmager P, et al.
Lancet Diabetes Endocrinol
. 2023 Oct;
11(11):811-821.
PMID: 37804858
Background: Faster-acting insulin aspart (faster aspart) is considered safe for use during pregnancy and breastfeeding but has not been evaluated in this population. We aimed to evaluate the effect of...
9.
Said M, Krogh J, Feldt-Rasmussen U, Rasmussen A, Kristensen T, Rossing C, et al.
J Neuroendocrinol
. 2023 Aug;
35(8):e13322.
PMID: 37564005
Guidelines for multiple endocrine neoplasia type 1 (MEN1) recommend intensive imaging surveillance without specifying a superior regimen, including the role of somatostatin receptor imaging (SRI) with positron emission tomography (PET)....
10.
Nesti C, Brautigam K, Benavent M, Bernal L, Boharoon H, Botling J, et al.
Lancet Oncol
. 2023 Jan;
24(2):187-194.
PMID: 36640790
Background: Awareness of the potential global overtreatment of patients with appendiceal neuroendocrine tumours (NETs) of 1-2 cm in size by performing oncological resections is increasing, but the rarity of this...